Brokerages Set Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Price Target at $32.88

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has been assigned a consensus recommendation of “Buy” from the thirteen research firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $32.88.

Several research analysts recently weighed in on DRNA shares. Citigroup dropped their target price on shares of Dicerna Pharmaceuticals from $39.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Stifel Nicolaus upped their target price on shares of Dicerna Pharmaceuticals from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Chardan Capital reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Sunday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dicerna Pharmaceuticals in a report on Sunday. Finally, BidaskClub downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 18th.

DRNA traded up $0.62 during mid-day trading on Friday, reaching $18.01. 440,325 shares of the company traded hands, compared to its average volume of 723,498. The stock has a market capitalization of $1.33 billion, a P/E ratio of -10.23 and a beta of 2.37. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.13. The company’s fifty day moving average price is $18.98 and its 200-day moving average price is $19.31. Dicerna Pharmaceuticals has a 52-week low of $10.70 and a 52-week high of $27.68.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.50). The company had revenue of $7.08 million for the quarter, compared to analysts’ expectations of $26.40 million. Dicerna Pharmaceuticals had a negative net margin of 503.93% and a negative return on equity of 76.93%. As a group, sell-side analysts forecast that Dicerna Pharmaceuticals will post 1.21 earnings per share for the current fiscal year.

In related news, COO James B. Weissman sold 4,360 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $21.88, for a total value of $95,396.80. Following the sale, the chief operating officer now directly owns 23,360 shares of the company’s stock, valued at approximately $511,116.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bob D. Brown sold 11,941 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $22.00, for a total transaction of $262,702.00. Following the completion of the sale, the insider now directly owns 17,855 shares in the company, valued at $392,810. The disclosure for this sale can be found here. Insiders have sold a total of 89,360 shares of company stock valued at $1,900,101 in the last three months. Insiders own 21.28% of the company’s stock.

A number of institutional investors have recently bought and sold shares of DRNA. Point72 Asset Management L.P. purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth about $27,763,000. Renaissance Technologies LLC raised its stake in shares of Dicerna Pharmaceuticals by 104.4% during the fourth quarter. Renaissance Technologies LLC now owns 992,400 shares of the biopharmaceutical company’s stock valued at $21,863,000 after purchasing an additional 507,000 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter valued at approximately $21,852,000. Marshall Wace LLP raised its stake in shares of Dicerna Pharmaceuticals by 531.0% during the fourth quarter. Marshall Wace LLP now owns 979,870 shares of the biopharmaceutical company’s stock valued at $21,586,000 after purchasing an additional 824,583 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Dicerna Pharmaceuticals by 22.2% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 879,500 shares of the biopharmaceutical company’s stock valued at $19,375,000 after purchasing an additional 160,000 shares during the period. 77.93% of the stock is currently owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Further Reading: What is the cash asset ratio?

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.